All In Biotech

NDA 216158 · Bristol-Myers

Cobenfy

Trospium Chloride, Xanomeline Tartrate · Oral · Cholinergic Muscarinic Agonist

Novel

CDER novel approval, Sep 26, 2024: To treat schizophrenia

Last checked: Nov 20, 2026Latest source record: Sep 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Sep 26, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

26 Phase 3, 23 recruiting

FAERS reports

2,767

669 serious, 29 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 16, 2026.

COBENFY is indicated for the treatment of schizophrenia in adults. COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, indicated for the treatment of schizophrenia in adults. ( 1 )

Mechanism: The mechanism of action of xanomeline in the treatment of schizophrenia is unclear; however, its efficacy is thought to be due to its agonist activity at M1 and M4 muscarinic acetylcholine receptors in the central nervous system. Trospium chloride is a muscarinic antagonist. Trospium chloride antagonizes the muscarinic receptors primarily in the peripheral tissues.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 26, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
  • COBENFY · TROSPIUM CHLORIDE 30MG; XANOMELINE TARTRATE EQ 125MG BASE · CAPSULE, ORAL · Prescription
  • COBENFY · TROSPIUM CHLORIDE 20MG; XANOMELINE TARTRATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
  • COBENFY · TROSPIUM CHLORIDE 20MG; XANOMELINE TARTRATE EQ 100MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trospium Chloride" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea593
  • vomiting439
  • constipation202
  • off label use195
  • urinary retention153
  • dizziness127
  • dyspepsia112
  • hyperhidrosis97
  • vision blurred92
  • drug ineffective84
  • dry mouth82
  • heart rate increased65

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2024172
20251,254
20261,341

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cobenfy (Xanomeline Tart/Trospium Chlor)

2024 spending

$2.4M

Beneficiaries

961

1,539 claims

Per beneficiary

$2,455

$31.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$2,359,550

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.